NEW ORLEANSMultiple myeloma cells can be fused to dendritic
cells and the resulting fusion cells used to selectively kill myeloma
tumor cells in vitro, according to a poster presentation at the 41st
annual meeting of the American Society of Hematology (ASH).
We are trying to generate a vaccine for the treatment of
minimum residual disease in multiple myeloma in the post-transplant
setting, the reports lead author Noopur Raje, MD, said in
an interview with ONI. Dr. Raje is an instructor in medicine at
Harvard Medical School.
The approach we are using is to fuse the whole tumor cell to an
autologous dendritic cell with the hope of being able to present both
known and unknown antigens to the host, rather than presenting
just a single antigen, as many dendritic-cell-based vaccines do, Dr.
In the study, cells from two human multiple myeloma cell lines (HS
Sultan and SKO-007) were fused to dendritic cells from normal donors,
which were cultured in the presence of GM-CSF and interleukin-4.
The researchers then tested the ability of these fused cells,
multiple myeloma cells alone, and dendritic cells alone in vitro to
prime naïve cytolytic T cells to act against multiple myeloma
After three weekly stimulations, the cytolytic T cells primed with
fused cells had killed 35% to 45% of the tumor cells. In contrast, T
cells treated with just myeloma cells or just dendritic cells did not
cause cell lysis in tumor cells.
Weve gone on to do patient samples, Dr. Raje added,
and weve seen that the patients own T cells
actually respond to this kind of approach.
In autologous mixed lymphocyte reactions using T cells derived from
patients, fused cells (but not myeloma cells alone or dendritic cells
alone) caused autologous T cells to proliferate. Dr. Raje said he
hopes to begin a phase I clinical study early this year.